Biography
Dr. Ansuman Satpathy M.D., Ph.D. in the Department of Pathology at Stanford University School of Medicine. He is a member of the Stanford Cancer Institute, the Parker Institute for Cancer Immunotherapy, the Immunology, Cancer Biology, and Biomedical Informatics Programs, Bio-X, and a faculty fellow in ChEM-H. Dr. Satpathy completed an M.D. and Ph.D. in immunology at Washington University in St. Louis, clinical residency in pathology at Stanford Hospital and Clinics, and postdoctoral training in genetics at Stanford University. Dr. Satpathy’s research group focuses on developing and applying genome-scale technologies to study fundamental properties of the immune system in health, infection, and cancer.

Biography
Peter is a Rheumatologist & Immunologist who immerses himself in basic & clinical research. He received his medical degree from the New York University School of Medicine, completed residency training at the Strong Memorial Hospital in Rochester, New York and his post-doctoral fellowship in NIAID at the NIH. After going to UT Southwestern Medical Center at Dallas, Peter rapidly advanced to become a professor of Internal Medicine and Microbiology as well as the Director of the Harold C Simmons Arthritis Research Center and, Co-Director of the Immunology Graduate Program. He entered the new millennium as the Director of the Intramural Research Program & the Autoimmunity Branch of NIAMS at the NIH. Peter is the co-founder and CEO of AMPEL BioSolutions LLC, a biotech company involved in employing analysis of BigData and Machine Learning to provide personalized medicine. Peter is the former editor of the Journal of Immunology, Nature Reviews Rheumatology and Arthritis Research & Therapy, and is the recipient of the Carol Nachman Prize, the American College of Rheumatology Distinguished Investigator Award and the Arthritis Foundation’s Lee Howley prize.

Biography
Mark Jacobstein is the Executive Business Advisor and former CBO for Immunai, a high growth startup using single cell genomics and ML to reprogram the immune system. Mark came to Immunai from Guardant Health, where he spent four years as the CUEO. Prior Mark was CEO of mobile VOIP-pioneer iSkoot until its acquisition by Qualcomm. Mark was also an EVP at loopt (sold to GreenDot) and the co-founding President of Sequoia-backed Digital Chocolate, a pioneer in mobile games. In 1994 Mark founded Small World Sports, the world's first online fantasy sports business, and served as CEO until he sold the business to Paul Allen in 2002. Mark also co-founded Small World Software, which he sold to iXL, where he served as SVP of business development through their 1998 IPO. 

Biography
Dr. Collins has spent the past 20 years as a biologist, strategist, and operational leader focused on transforming and scaling biopharma and healthcare companies. Previously, she was the Head of U.S. Clinical Operations at Genentech, where she was responsible for executing in-sourced, late-stage, pivotal clinical trials for the entire Genentech / Roche product portfolio. Prior to that, Dr. Collins was Vice President and General Manager for the U.S. Clinical Trial Sourcing business at McKesson Corporation and worked as a senior executive focused on life sciences strategy and operations for Fortune 500 companies at Deloitte and Quintiles Consulting. Dr. Collins is also an Aspen Institute Health Innovator Fellow, an independent Corporate Director for IDEXX Laboratories, a member of the Scientific Advisory Board for the Translational Research Institute for Space Health, and a mentor for Backstage Capital. She also worked on The Cancer Genome Atlas project (TCGA), where she focused on managing stakeholder and public communications, as well as the integration of business requirements for the first public database. Dr. Collins earned her PhD in Cancer Biology from the University of Wisconsin-Madison and a Bachelor of Science in Biology from the University of Pittsburgh.

Talk
Cloud-based Research Analytics of Large Population Cohorts
There are multiple large, population cohorts coming online and being planned. We will discuss how cloud-based analytic platforms are allowing innovation and discovery for the maximum number of researchers and as a result the greatest impact on advancing science and healthcare.

Biography
Alex's focus at Khosla Ventures is in biotechnology, healthcare, data science, and AI/ML. Alex has an MD and PhD in biomedical informatics from Stanford, with a dissertation on machine learning methods in precision medicine under the supervision of Atul Butte. Alex has completed additional graduate work in biology and physics and a short postdoctoral fellowship in biochemistry and genetics with Ronald W. Davis at the Stanford Genome Technology Center. As a scientist, he has published over 50 scientific publications, primarily at the intersection of computer science, biology, and healthcare. As an inventor, he has licensed IP to three separate companies. As an entrepreneur, he has worked as an early employee or co-founder at a range of startups. He currently sits on the boards of some of Khosla Ventures’ investments, including Deep Genomics and HeartVista. Alex is committed to improving access to healthcare to underserved communities through community service, and served as co-manager of the volunteer-staffed Arbor Free Clinic in Menlo Park, where he also worked as head of IT and helped develop and deploy their electronic medical records system. Alex is particularly interested in helping to advance diversity in STEM fields, including technology entrepreneurship.

Biography
Cornelis E.C.A. “Marcel” Hop is Vice-President at Genentech and supervising the DMPK department. He leads a team of about 85 scientists involved in acquisition and interpretation of ADME data in support of drug discovery and development ranging from early stage research to NDA and beyond. Before that, he was a Senior Director at Pfizer and a Senior Research Fellow at Merck and he received his Ph.D. from the University of Utrecht (The Netherlands). He has extensive experience in ADME sciences with a particular focus on PK optimization, human PK prediction, biotransformation, bioanalysis and the use of in silico approaches in drug discovery.

Biography
Stacie is a pharmaceutical R&D and biotech leader with expertise in AI and machine learning applications for drug discovery. At BioSymetrics she guides the company on its drug discovery and partnering strategies, with a focus on translating human-relevant disease biology. Prior to BioSymetrics, Stacie led collaborations and partnerships in the AI-powered drug discovery space as Vice President and Head of AI Molecular Screening Partnerships at Atomwise. Previously she established and co-led the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium, a public-private partnership developing machine learning tools to accelerate drug discovery. She worked at GSK for more than 13 years, starting as a process chemist and moving up into R&D strategy and operations roles where she led several change initiatives and teams. Stacie holds a B.S. in Chemistry from University of California Berkeley and a Ph.D. in chemistry from University of California Irvine.

Biography
Dr. Tommaso Mansi is currently leading the AI/ML and Digital Health team at the Janssen R&D Data Science division. Dr. Mansi’s focus is on the development of AI solutions that enable deriving actionable insights from multimodal, multiscale data, to support and help accelerate drug discovery and development. Prior to joining Janssen, Dr. Mansi was at Siemens Healthineers, Digital Technology and Innovation. Dr. Mansi’s research interests cover artificial intelligence in healthcare, medical imaging, computational physiology, AI for biology, and image-guided therapy. Dr. Mansi received several awards for his work, gave multiple keynotes at international conferences and events. He holds 60+ granted US patents, co-edited 1 monograph and co-authored 100+ scientific publications.

Biography
Mika has more than 20 years of commercial strategy and leadership experience in life sciences, with a focus on novel technologies. Over the last 10 years, Mika has concentrated on evidence-based medicine and tools to transform healthcare and clinical development. Before joining xCures Mika was the Chief Commercial Officer of Doctor Evidence, LLC. Prior to Doctor Evidence he was the General Manager of Clinical Development Services at diaDexus, SVP of Client and Market Development at Evidera, VP of Sales and Marketing at Archimedes, and held sales management and sales operations roles at Quintiles, Invitrogen and Tripos.

Biography
Kevin leads the business development efforts to form research collaboration partnerships with biopharma companies. Over the years, Kevin has worked in small-to-midsize biotechs and CROs gathering a wide spectrum of experience in pre- and post-IND development. With his previous role at Integrium, he has helped kickstart an investment arm leading equity and bridge financing investments with micro-cap and small-cap public biopharma companies.

Talk
AI-driven Drug Discovery Platform for Splicing Driven Diseases
Introduction to Envisagenics’ SpliceCore drug discovery platform and its application of RNA-splicing analytics to identify new therapeutic targets. The impact of transparent machine learning algorithms for downstream experimental validations. Case study – translating a novel splicing derived target identified by SpliceCore into the wet lab.

Biography
Martin-Immanuel Bittner is the CEO of Arctoris, a biotech company combining wet lab automation and machine learning for accelerated small molecule drug discovery. Martin graduated as a medical doctor from the University of Freiburg in Germany, followed by his DPhil in Oncology as a Rhodes scholar at the University of Oxford, where he co-founded Arctoris. He has extensive research experience covering both clinical trials and preclinical drug discovery and is an active member of several leading cancer research organisations, including EACR, AACR, and ESTRO. Martin is a Fellow of the RSA and an elected member of the Young Academy of the German National Academy of Sciences and of Sigma Xi.

Biography
William K. Oh, M.D. is Chief Medical Science Officer at Sema4, a patient-centered health intelligence company focused on precision medicine. He is also an internationally recognized medical oncologist with over 25 years of clinical and translational research experience and leadership roles at major NCI-designated cancer centers. He continues to see cancer patients in his capacity as Clinical Professor of Medicine at Icahn School of Medicine at Mount Sinai. William has authored more than 330 articles, reviews, books and book chapters related to genitourinary cancers. He has conducted multiple clinical cancer trials and has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association.

AI & Data Science Showcase:
Sema4
Sema4 is a Patient-Centered Health Intelligence Company Leveraging AI, Genomics and Other Deep Data.

REPRESENT: Providing Prec. Oncology Access to All
Sema4 launched the REPRESENT study in community oncology practices caring for patients with advanced cancer in diverse, underserved populations. REPRESENT will perform comprehensive genomic profiling, hereditary cancer testing and clinical data including SDOH and correlate outcomes to these findings.

Biography
Jim Edwards is currently leading a multi-disciplinary group of computational & data scientists providing predictive and design tools across all modalities within the Therapeutics Discovery organization at Janssen, starting at project inception through the identification of clinical candidates. Primary to this, Jim was US Regional Head, Discovery Chemistry at Janssen Research & Development, leading drug discovery teams in South Francisco & La Jolla CA, Boston, MA, and Spring House, PA. These teams were responsible for the design and synthesis of small molecule drug candidates working with partners across DPDS and all six Therapeutic Areas within JRD. From 1999-2014, Jim led various Immunology medicinal chemistry groups at Janssen which delivered clinical-stage molecules against multiple novel first-in-class targets. Jim received his Ph.D. from the University of Illinois, Urbana-Champaign, working with Professor Scott Denmark, and performed post-doctoral studies with Professor Lanny Liebeskind at Emory University.

Biography
Since coming to Epic more than 25 years ago with a background in physics and mathematics, Peter has designed, developed, and implemented a broad array of EHR-related technology at some of the world’s most well-known healthcare institutions, helping along the way to foster widespread interoperability between providers, patients, laboratories, and other partners. For the last several years, he has helped lead Epic’s precision medicine efforts, transforming genomics into computable data for clinical care and research.

Biography
Cell Biologist studying the intersection of metabolism, stem cell and regenerative biology, and aging.

Biography
Kristen Fortney is the co-founder and CEO of BioAge, a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging. By targeting these pathways with a large and mechanistically diverse portfolio of drugs, BioAge will unlock opportunities to treat or even prevent diseases of aging in entirely new ways. Kristen’s scientific background is in aging biology and bioinformatics. She received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University where she was a fellow of the Ellison Medical Foundation / American Federation for Aging Research.

Biography
Steve joined Engine Biosciences as Chief Scientific Officer in May 2018. Prior to joining Engine, Steve was Senior Vice President and CSO at Relypsa where he developed a pipeline of gut-restricted polymer therapeutics targeting systemic diseases. Before that he was Vice President, Research Biology at Nektar Therapeutics (NASDAQ: NKTR), a leader in polymer conjugate therapeutics, where for four years he managed global oncology and pain research efforts. Prior to Nektar, he was Senior Vice President, Research at KAI Pharmaceuticals. While at KAI, Steve led discovery efforts, including the company’s lead compound for the treatment of secondary hyperparathyroidism, which served as the basis for the company’s eventual acquisition by Amgen. Earlier in his career, Steve held senior research positions at Chiron Corporation and Thios Pharmaceuticals. He holds a Ph.D. in Molecular Biology, a M.A. and B.A. in Biochemistry, all from University of Cambridge, England.

Talk
Target and Biomarker Identification Using ML and CRISPR Screening
Engine Biosciences is uniquely applying proprietary machine-learning algorithms and ultra high-throughput CRISPR-based validation technology to identify clinically relevant targets and patient selection biomarkers in oncology. In our talk we would outline the differentiating features of the technology platform and showcase case studies of successful target and biomarker discovery leading to drug development programs.

Biography
Quin is an MD/PhD with few extra degrees in genomics, mathematics, and statistical/machine learning. He uses deep genomic phenotyping technologies to develop RNA therapies for chronic liver disease. He started his first liver genomics company 17 years ago, and was most recently Head of Cellular and Systems Genomics for Novo Nordisk before co-founding Ochre Bio. Ochre Bio is a series A company, with labs in Oxford, Taipei, and New York where they regenerate human livers not good enough for transplantation. Think farms of livers on machines being refurbished by direct RNA reprogramming, so that fewer patients die waiting for a new liver.

Biography
Originally a specialist in systems biology, Lindsay joined GlaxoSmithKline in 2014 from the faculty of King’s College London. He started GSK’s first Data Science group, before becoming VP of AI/ML Engineering. He joined AstraZeneca as VP of AI in 2020, delivering complex models into production and publishing in some of machine learning’s most respected forums. He also led a small data science team working on the critical path of the Oxford-AstraZeneca COVID vaccine. His background spans machine learning, data science and bioinformatics but also human physiology, metabolic biochemistry and metabolomics. He has previously held academic appointments in both Australia and the UK. He holds a DPhil in Physiology from Oxford, has published more than 40 articles in peer-reviewed journals and is an accomplished public speaker. Before becoming a scientist, he was a successful musician and record producer and counts a number of UK Top Ten singles and multiple platinum albums to his credit.

Biography
Nasim leads the applied AI and data science department at City of Hope, one of the largest cancer research and treatment organizations in the United States. She helps supervise teams that are responsible for applying machine learning in clinical decision support and patient care, research, and precision medicine, as well as operations and finance. Before joining City of Hope in 2017, Nasim co-founded an AI company focusing on social media data mining and financial markets and political events prediction. She continues to advise startup companies on successful implementation of AI solutions. Nasim holds a master’s degree in computer science from Southern Illinois University and a bachelor’s degree in computer engineering from Khaje Nasir Toosi University in Tehran, Iran. On a personal level, Nasim enjoys an active lifestyle in sunny Los Angeles and has a passion for fitness and sports. She plays soccer and beach volleyball and goes to the gym every day!

Biography
Calum MacRae is a physician and scientist who works on disease mechanisms, translational genomic medicine and digital innovation. He is the PI of the AHA/Verily/AstraZeneca/Quest Diagnostics funded One Brave Idea program and the Apple Heart & Movement Study, as well as an Associate Member of the Broad Institute of Harvard and MIT and a Principal Faculty Member in the Harvard Stem Cell Institute. He was previously Chief of Cardiovascular Medicine at Brigham and Women's Hospital.

Talk
Encoding disease biology to automate care delivery
Data ingestion in medicine is typically a series of incompletely linked episodes. Systematizing all care transactions at an individual patient level offers the potential to create the data streams necessary to optimize chronic disease management, stratify individual risk in novel ways and reimagine clinical workflows.

Biography
Andrew leads product development for the genomics team in Google Health. The genomics team develops methods that improve real-world applications in clinical genomics, population-level sequencing, drug discovery, and the combination of genomic and clinical data. Prior to Google, Andrew was Chief Scientific Officer at DNAnexus, where he supported many of the first large-scale genomics projects, such as the CHARGE Consortium, Regeneron-Gesinger and Regeneron-UKBiobank cohorts, the 3000 Rice Genomes Project, PrecisionFDA, and the St. Jude Pediatric Cancer Cloud. Andrew holds a PhD in Molecular Biology from Stanford University and a Bachelor’s degree in Physics from the University of Virginia.

Talk
DeepConsensus: Sequence Transformers for Sequence Correction
DeepConsensus improves accuracy for Pacific Biosciences sequencing output using a ML method called a transformer. This talk details how we optimized the training of the transformer for biological sequence data. By designing the model architecture with domain-specific insights in mind, we walk through how we achieve substantial improvements to accuracy and analysis speed.

Biography
Lucy Burkitt-Gray leads a team of Data Analysts and Bioinformaticians based at the headquarters of UK Biobank in Manchester, UK. Lucy moved to UK Biobank in 2019, and has since worked to deliver to the public large new datasets such as whole exome and whole genome sequencing of UK Biobank's 500,000 participants. Lucy is passionate about widening access to highly valuable research cohorts, and as such is proud to be part of the transformation of the UK Biobank resource onto their cloud-based Research Analysis Platform. Lucy has a PhD in Computational Infection Biology from University College Dublin, and an MA in Natural Sciences from the University of Cambridge.

Biography
Lisa has a background in math and computer science and a PhD in Bioinformatics, with over 15 years experience in software and methods that bridge genomic and clinical data to advance the understanding of biology and improve patient care. In her role at AWS, Lisa develops strategy and tactical initiatives for the genomic industry to implement best practices for cloud workloads and define solutions for innovative and emerging applications. Building from her experience in cancer research from Fred Hutch, she is dedicated to lowering barriers in data analysis to facilitate collaborative and reproducible research as well as accelerate translation into clinical outcomes.

Biography
Marty Tenenbaum is a renowned computer scientist, Internet entrepreneur and cancer warrior. He is the Founder and Chairman of Cancer Commons, a non-profit network of physicians, scientists, and patients that Newsweek dubbed the “LinkedIn of Cancer.” He began his career in AI, leading elite research groups at SRI International and Schlumberger Ltd. Later, as an Internet commerce pioneer, he founded or co-founded five successful startups. Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, a former Director of Commerce One, the Public Library of Science (PLoS) and Patients Like Me, and a former consulting professor of Computer Science at Stanford. He currently serves as a Director of CommerceNet and Efficient Finance. Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford, and has received numerous awards for his contributions to AI and his work as a patient advocate.